Reversing endothelial dysfunction with empagliflozin to improve cardiomyocyte function in cardiorenal syndrome.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33892855.
- Also identified by DOI 10.1016/j.kint.2021.01.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sodium-glucose cotransporter 2 inhibitors offer cardiovascular and renal benefits in patients with chronic kidney disease through not yet clearly defined mechanisms. Juni et al. showed that sodium-glucose cotransporter 2 inhibitor empagliflozin exposure in vitro can restore cardiomyocyte function by counteracting harmful effects of uremic serum on the endothelium-cardiomyocyte crosstalk between endothelial cells and cardiomyocytes. The author's findings improved our understanding of cardiovascular impairment in chronic kidney disease and provided new perspectives for the beneficial effects of sodium-glucose cotransporter 2 inhibitor therapy.
Medical subject headings
- Cardio-Renal Syndrome
- Renal Insufficiency, Chronic
- Sodium-Glucose Transporter 2 Inhibitors